gip/glp-1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Dual GLP-1/GIP Agonist | Tirzepatide

They can also help type 1 diabetes patients lose weight, something thats especially difficult for people who take insulin, which signals the body to take extra sugar out of the blood and store it as fat

This helps stabilise blood sugar levels and contributes to improved appetite regulation

The best way to understand the risks of GLP-1s and menopause is to speak with a care provider about health concerns, medical history, and overall goals

Further competition comes from tirzepatide, approved by the FDA in 2022 and now sold under the Mounjaro/Zepbound brand name

High risk (red): do not prescribe GLP-1 RAs in these situations, because of lack of evidence, high risk of AEs or licence restrictions